1. 618OHealth-related quality of Life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR). (18th September 2017) Authors: Vogel, A.; Qin, S.; Kudo, M.; Hudgens, S.; Yamashita, T.; Yoon, J-H.; Fartoux, L.; Simon, K.; López López, C.; Sung, M.; Dutcus, C.; Kraljevic, S.; Tamai, T.; Grunow, N.; Meier, G.; Breder, V. Journal: Annals of oncology Issue: Volume 28(2017)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2864 Defining 131I-refractory differentiated thyroid cancer: efficacy and safety of lenvatinib by 131I-refractory criteria in the SELECT trial. (September 2015) Authors: Kiyota, N.; Robinson, B.; Shah, M.; Hoff, A.O.; Taylor, M.; Li, D.; Dutcus, C.; Lee, E.K.; Kim, S.B.; Tahara, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S578 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2805 Overall survival gain with lenvatinib vs. placebo in radioactive iodine refractory differentiated thyroid cancer (RR-DTC): An updated analysis. (September 2015) Authors: Guo, M.; Sherman, S.; Wirth, L.; Schlumberger, M.; Dutcus, C.; Robinson, B.; Tahara, M.; Latimer, N. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S559 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗